More recently, Bersanelli et al. identified distinct MDS clusters linked to specific genomic features, defining distinct genomic groups with unique outcomes: no specific genomic abnormalities, SF3B1 related, TP53/complex karyotype, SRSF2 related, U2AF1 associated 20q deletion or chromosome 7 abnormalities, and finally AML-like mutation patterns. This evidence concerns the gene TP53 and acute myeloid leukemia.